Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
Protocol 08
Study information
Scientific title
Does 1-alpha, 25-dihydroxyvitamin D3 (calcitriol) enhance corticosteroid activity in steroid refractory asthma? A randomised controlled trial
Acronym
VitD1/08
Study hypothesis
We hypothesise that the administration of the active form of vitamin D (calcitriol) improves the clinical response to systemic corticosteroid therapy in patients with moderate to severe asthma whose symptoms fail to improve on steroid therapy.
Ethics approval
Guys Research Ethics Committee, 01/08/2008, ref: 08/H0804/84
Study design
Randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Asthma
Intervention
Screen visit 1:
Informed consent will be obtained before screening starts. Suitable subjects will undergo full assessment of their medical history (including a complete smoking history) and laboratory evaluation for safety haematology and biochemistry profile. Up to 100 ml of venous blood will also be drawn for ex-vivo experiments. Spirometry will be performed and the FEV1 and forced vital capacity (FVC) obtained. Reversibility would be assessed by giving the subject a short acting beta agonist and measuring the FEV1 pre- and 15 - 30 minutes post-bronchodilator. We will measure fractional exhaled nitric oxide (FeNO) using an Aerocrine NIOX MINO® monitor following the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines. A peak flow meter and a diary card will be given to the subject to record morning and evening peak flows throughout the study. All these procedures are done in accordance with departmental Standard Operating Procedures.
Eligible subjects would be entered into the second part of the screening process. These subjects would be given prednisolone 40 mg/1.73 m^2/day as a single dose in the morning for 14 days, to be taken at home.
Screen visit 2:
The subject's medical history and adverse events would be reviewed at the start of the screening visit 2. Spirometry will be performed and the FEV1 and FVC obtained. Subjects who demonstrate an increase of greater than 15% in the FEV1 when compared to baseline (screen visit 1) would be excluded. Subjects who are still eligible would be entered into the main part of the trial. We will repeat FeNO in exhaled air. Up to 100 ml of venous blood will be taken for safety haematology and biochemistry and for ex-vivo experiments.
Treatment visit day 1:
Following a 4-week washout period (from screen visit 2) participants would attend treatment visit day 1. The subjects' medical history and adverse events would be reviewed at the start of this visit. Up to 100 ml of venous blood would be taken for safety haematology and biochemistry and for ex-vivo experiments. Participants would be randomised to receive either calcitriol 0.25 mg twice daily or matching placebo. The first dose would be done under supervision. Subjects would be discharged following first dosing and would take the subsequent doses at home.
Treatment visit day 15:
On day 15 of treatment subjects would attend treatment visit day 15. Subjects are to withhold their day 15 treatment dose prior to attending. The subjects medical history and adverse events would be reviewed at the start of this visit. Prior to dosing up to 100 ml of venous blood would be taken for safety haematology and biochemistry and for ex-vivo experiments. Subject would perform spirometry and fraction of nitric oxide in exhaled air (FeNO) pre-dose. These would be done in accordance with departmental standard operating procedures. A standard Asthma Control Questionnaire (ACQ) would also be completed by the subject pre-dose.
FeNo measurements are highly correlated with eosinophilic airway inflammation; eosinophilic inflammation is correlated with response to steroid treatment. We will measure FeNO using a Aerocrine NIOX MINO® monitor, following the ATS/ERS guidelines.
Subjects who are still eligible to continue in the study would be commenced on prednisolone 40 mg/1.73 m^2/day as a single dose for 14 days. The first dose of prednisolone and day 15 dose of treatment article would be done under supervision. Subjects would be discharged following dosing and would take subsequent doses of treatment and prednisolone at home.
Treatment visit day 28:
On day 28 of treatment subjects would attend treatment visit day 28. Subjects would have completed a 28-day dosing period of treatment article and a 14-day dosing period of prednisolone. The subject's medical history and adverse events would be reviewed at the start of this visit. Following this up to 100 ml of venous blood would be taken for safety haematology and biochemistry and for ex-vivo experiments. Subject would perform spirometry, and fraction of nitric oxide in exhaled air (FeNO). A standard Asthma Control Questionnaire (ACQ) would also be completed by the subject. A physical examination would also be performed.
Follow-up day 56:
After 1 month subjects will be interviewed either during a routine visit to the asthma clinic or via telephone call to check medical history and adverse events. Following all these procedures subjects would be discharged from the study.
Intervention type
Supplement
Phase
Not Specified
Drug names
Vitamin D3 supplementation
Primary outcome measures
Change in FEV1 at baseline compared to the end of the treatment period.
Secondary outcome measures
1. Level of the ex-vivo production of interleukin-10 (IL-10) and other surrogate biomarkers of outcome or drug effects/process by T-cells, measured at screen visit 1, screen visit 2, treatment visit day 1, treatment visit day 15 and treatment visit day 28
2. Serological markers of inflammation, measured at screen visit 1, screen visit 2, treatment visit day 1, treatment visit day 15 and treatment visit day 28
3. Fraction of nitric oxide in exhaled air, measured at screen visit 1, screen visit 2, treatment visit day 15 and treatment visit day 28
4. Asthma Control Questionnaire (ACQ) score, measured at treatment visit day 15 and treatment visit day 28
Overall trial start date
01/04/2009
Overall trial end date
30/09/2011
Reason abandoned
Eligibility
Participant inclusion criteria
1. Male or female adults aged between 18 to 65 years
2. Documented history and typical symptoms of asthma for greater than or equal to 6 months prior to screening
3. Pre-bronchodilator forced expriatory volume in one second (FEV1) less than 70% predicted and greater than 15% reversibility to beta 2-agonist or diurnal peak flow variability of greater than 20%
4. Corticosteroid refractory asthma, as defined by a less than 15% improvement in FEV1 following a 14-day course of prednisolone 40 mg/1.73 m^2/days 29 - 31
5. Written informed consent received
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
80
Participant exclusion criteria
1. Past or present disease, which, as judged by the investigator, may affect the study outcome (other than asthma, rhinitis or eczema)
2. Serum corrected calcium greater than 2.66 mmol/l
3. Clinically significant deviation from normal (physical examination or laboratory parameters) as judged by the investigator at the screening visit
4. Current smoker or an ex-smoker of less than 5 years with a greater than 5 pack year history
5. Pregnant or lactating females or those at risk of pregnancy (women of childbearing age may be offered a pregnancy test prior to recruitment)
6. History of a respiratory tract infection and/or exacerbation of asthma within 4 weeks of the screening visit requiring oral corticosteroid tablets
7. Participation in a study involving an investigational medicinal product in the previous 3 months or blood donation within the last year
8. Participants taking regular medications for diseases other than those for asthma or rhinitis
9. Current or previous allergen immunotherapy
10. Concomitant treatment with a thiazide diuretic or calcium supplement
11. Inability to understand or comply with the research protocol
Recruitment start date
01/04/2009
Recruitment end date
30/09/2011
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Department of Asthma, Allergy and Respiratory Allergy
London
SE1 9RT
United Kingdom
Sponsor information
Organisation
Kings College London (UK)
Sponsor details
c/o Jackie Pullen
3rd floor Conybeare House
Guys Hospital
Great Maze Pond
London
SE1 9RT
United Kingdom
Sponsor type
University/education
Website
Funders
Funder type
Charity
Funder name
Asthma UK (UK)
Alternative name(s)
Funding Body Type
private sector organisation
Funding Body Subtype
other non-profit
Location
United Kingdom
Funder name
Friends of Guy's Hospital (UK)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary
2014 results in: http://www.ncbi.nlm.nih.gov/pubmed/24786237
Publication citations
-
Results
Nanzer AM, Chambers ES, Ryanna K, Freeman AT, Colligan G, Richards DF, Timms PM, Martineau AR, Griffiths CJ, Corrigan CJ, Hawrylowicz CM, The effects of calcitriol treatment in glucocorticoid-resistant asthma., J. Allergy Clin. Immunol., 2014, 133, 6, 1755-7.e4, doi: 10.1016/j.jaci.2014.03.015.